So-Young International Inc. (SY) Earnings
So-Young International Inc. is expected to report next earnings on November 23, 2026 (in NaN days), with a consensus EPS estimate of $-0.08. SY has beaten EPS estimates in 7 of its last 12 reported quarters (average surprise +38.1% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 31, 2026 | $-0.09 | $-0.03 | +65.9% | $74M | +6.2% |
| May 22, 2026 | $-0.10 | $-0.07 | +33.3% | $63M | +5.9% |
| Mar 25, 2026 | $-0.10 | $-0.13 | -33.5% | $66M | +6.7% |
| Nov 17, 2025 | $-0.68 | $-0.09 | +86.8% | $54M | -87.7% |
| Aug 15, 2025 | $-0.33 | $-0.04 | +88.0% | $53M | -86.3% |
| May 16, 2025 | $-0.34 | $-0.04 | +88.2% | $41M | -88.6% |
| Mar 28, 2025 | $0.09 | $-0.07 | -177.8% | $51M | -82.8% |
| Nov 20, 2024 | $0.02 | $0.03 | +50.0% | $53M | +5.8% |
| Aug 23, 2024 | $0.21 | $0.02 | -90.5% | $56M | +10.2% |
| May 28, 2024 | $0.01 | $0.07 | +833.3% | $55M | +30.1% |
| Mar 20, 2024 | $0.15 | $0.06 | -60.0% | $44M | -14.1% |
| Nov 20, 2023 | $0.15 | $0.01 | -93.3% | $53M | +7.0% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 31, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Strategic Growth and Expansion: - Continued implementation of the 'two-wheel drive' strategy, focusing on offline joint operations and professional medical capabilities. - Xing Yang Youth Clinic expanded into 18 cities with 65 centers as of Q2 2026, achieving triple-digit year-over-year growth in service volume (up 145%) and active users (surpassing 250,000). - Same-store sales growth improved significantly to 52%, compared to 14% in the prior year period. Operational Efficiency and Profitability: - Net loss attributable to the company narrowed by 37% year-over-year to RMB 22.7 million. - Gross margin for aesthetic treatment services improved by 3.8 percentage points year-over-year to 28.1%. - Number of profitable centers rose to 47, and 51 centers generated positive operating cash flow. - Raised bed capacity utilization benchmark by 50% (from 10 to 15 treatments per day) to enhance operating leverage and reduce customer wait times. Supply Chain and Product Innovation: - Launched new products including 'Miracle Collagen' (joint product with Jinbo Biopharmaceutical, >66,000 units sold) and 'Waveco/Vimei VUCO' (soft cross-linking technology). - Shifted from traditional buyer-vendor relationships to a co-creation model with upstream manufacturers, utilizing real-world data to guide product development and inventory planning. - Expanded physician team to ~280 full-time doctors and enhanced training through partnerships with manufacturers like Allergan and Jingbo. AI and Digital Integration: - Focusing on AI integration to support physicians, ensure medical safety, and standardize service delivery. - Building a real-world database and clinical AI infrastructure to improve user experience and upstream R&D. - Launching a user-facing virtual medical dispensing platform and dual-screen SOP displays to boost trust. - Planned launch of first-generation fully intelligent centers in Q4 2026.
Guidance
- Aesthetic Treatment Services Revenue Guidance: Management raised guidance for the next quarter, expecting revenues between $352 million and $362 million. - Expected Growth Rate: This represents a year-over-year growth rate of 91.7% to 97.2%. - Margin Outlook: Management expressed confidence in ongoing gross margin improvement driven by scale effects, supply chain leverage, and operational efficiency gains.
Segment performance
Aesthetic Treatment Services: Revenue reached RMB 331.4 million (approx. $330-331M), up ~130% year-over-year, representing approximately 65% of total group revenue. This segment drove the company's record quarterly revenue and contributed to a narrowed net loss. Information and Reservation Services: Revenue was RMB 187.9 million, down 35% year-over-year due to fewer medical service providers subscribing to information services. Medical Products and Maintenance Services: Revenue was RMB 73.9 million, down 2.8% year-over-year primarily due to decreased order volumes for medical equipment. Other Services: Revenue was RMB 12 million, down 48.2% year-over-year due to lower insurance brokerage revenue.
Risks & headwinds
- Regulatory and Compliance Risks: The company emphasizes strict adherence to medical safety, user privacy, and data compliance, particularly regarding AI applications and real-world data usage. - Operational Execution Risks: Rapid expansion requires maintaining high-quality medical delivery and standardized workflows across new centers; failure to do so could impact brand reputation and user trust. - Market Competition: Intense competition in the medical aesthetics sector necessitates continuous innovation in products and services to maintain market share. - Dependency on Key Partnerships: Reliance on strategic collaborations with upstream manufacturers (e.g., Jinbo, Allergan) for product co-creation and supply chain stability presents potential disruption risks if partnerships falter.
Analyst Q&A
Q: How does the collaboration with Jingbo/Xinbo benefit SoYoung, particularly regarding product development? /
A: Management highlighted that the partnership has evolved beyond simple supply chains to a co-creation model using real-world data. By analyzing consumer demographics, skin conditions, and treatment outcomes, SoYoung can precisely match products to specific needs, optimize doctor training, and reduce inventory guesswork. This data-driven approach allows upstream manufacturers to develop products based on actual clinical insights, accelerating innovation and enhancing operational efficiency.
Q: What is the strategic role of AI in SoYoung's business model? /
A: AI is positioned to empower physicians and standardize service quality rather than replace human expertise, ensuring safety and consistency. Current applications include QR code authentication for product traceability to build trust and using AI to analyze top physicians' techniques to create standardized SOPs. Looking ahead, SoYoung plans to launch its first generation of fully intelligent centers in Q4 2026, integrating AI deeply into clinical diagnosis and treatment workflows to scale premium care.
Q: What are the key drivers behind the significant improvement in gross margins? /
A: The 3.8 percentage point year-over-year increase in gross margin is driven by increased operational efficiency and scale. Specifically, SoYoung raised its bed utilization benchmark by 50% (from 10 to 15 treatments/day), optimizing workflows to reduce wait times and unlock operating leverage. Additionally, expanding network scale provides procurement advantages and bargaining power with suppliers, while a higher proportion of mature, profitable centers contributes to overall margin expansion.
Q: How does management view the path to group-level profitability given the current loss? /
A: Management attributes the current loss to strategic investment in the high-growth clinic business, which is offset by profits from stable cash-flow-generating segments like bubble and real estate sales. The core driver for loss reduction is focus: scaling back investments in non-core loss-making businesses while improving the operational efficiency and acquisition ROI of the clinic segment. With fixed costs anchored and contribution margins rising due to scale and efficiency, management expects the clinic business to reach profitability soon, aided by the upcoming peak autumn/winter season.